WO2004101758A3 - Composition for maintaining organ and cell viability - Google Patents

Composition for maintaining organ and cell viability Download PDF

Info

Publication number
WO2004101758A3
WO2004101758A3 PCT/US2004/014551 US2004014551W WO2004101758A3 WO 2004101758 A3 WO2004101758 A3 WO 2004101758A3 US 2004014551 W US2004014551 W US 2004014551W WO 2004101758 A3 WO2004101758 A3 WO 2004101758A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
cell viability
maintaining organ
organ
maintaining
Prior art date
Application number
PCT/US2004/014551
Other languages
French (fr)
Other versions
WO2004101758A2 (en
Inventor
Joseph Fischer
Jan Baker
Robert G L Shorr
Original Assignee
Lifeblood Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32991004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004101758(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lifeblood Medical Inc filed Critical Lifeblood Medical Inc
Priority to AU2004239310A priority Critical patent/AU2004239310B2/en
Priority to JP2006532912A priority patent/JP5192694B2/en
Priority to MXPA05012070A priority patent/MXPA05012070A/en
Priority to BRPI0410185-5A priority patent/BRPI0410185A/en
Priority to EP04751778.4A priority patent/EP1624750B1/en
Priority to CA2526933A priority patent/CA2526933C/en
Publication of WO2004101758A2 publication Critical patent/WO2004101758A2/en
Publication of WO2004101758A3 publication Critical patent/WO2004101758A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

The present invention is directed to nanoparticle compositions for maintaining organ, tissue and cellular viability when such are separated from normal physiological supports. Compositions containing the nanoparticle compositions and methods of preserving organs such as kidneys, both in vivo and ex vivo, are also disclosed.
PCT/US2004/014551 2003-05-09 2004-05-07 Composition for maintaining organ and cell viability WO2004101758A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2004239310A AU2004239310B2 (en) 2003-05-09 2004-05-07 Composition for maintaining organ and cell viability
JP2006532912A JP5192694B2 (en) 2003-05-09 2004-05-07 Composition for maintaining viability of organs and cells
MXPA05012070A MXPA05012070A (en) 2003-05-09 2004-05-07 Composition for maintaining organ and cell viability.
BRPI0410185-5A BRPI0410185A (en) 2003-05-09 2004-05-07 composition to maintain the viability of an organ and cell
EP04751778.4A EP1624750B1 (en) 2003-05-09 2004-05-07 Composition for maintaining organ and cell viability
CA2526933A CA2526933C (en) 2003-05-09 2004-05-07 Composition for maintaining organ and cell viability

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46920003P 2003-05-09 2003-05-09
US60/469,200 2003-05-09

Publications (2)

Publication Number Publication Date
WO2004101758A2 WO2004101758A2 (en) 2004-11-25
WO2004101758A3 true WO2004101758A3 (en) 2005-08-11

Family

ID=32991004

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2004/014551 WO2004101758A2 (en) 2003-05-09 2004-05-07 Composition for maintaining organ and cell viability
PCT/EP2004/004897 WO2004099393A1 (en) 2003-05-09 2004-05-07 Method for storing tumor cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/004897 WO2004099393A1 (en) 2003-05-09 2004-05-07 Method for storing tumor cells

Country Status (12)

Country Link
US (3) US7604933B2 (en)
EP (3) EP1475434A1 (en)
JP (2) JP4870551B2 (en)
KR (1) KR20060019525A (en)
CN (2) CN1784142A (en)
AU (2) AU2004236402B2 (en)
BR (1) BRPI0410185A (en)
CA (2) CA2523417C (en)
MX (1) MXPA05012070A (en)
RU (1) RU2005138320A (en)
WO (2) WO2004101758A2 (en)
ZA (1) ZA200509760B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105284786A (en) * 2015-10-15 2016-02-03 广州赛莱拉干细胞科技股份有限公司 Cell preservation liquid and application thereof in protecting megakaryocyte progenitor cell activity

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1475434A1 (en) * 2003-05-09 2004-11-10 Oncoscience AG Method for storing tumor cells
US7087369B2 (en) * 2003-12-17 2006-08-08 The Regents Of The University Of California Cornea preservation medium
JP2005306749A (en) * 2004-04-19 2005-11-04 Kringle Pharma Inc Hgf-containing preserving liquid for organ
ES2348736T3 (en) 2004-10-07 2010-12-13 Transmedics, Inc. SYSTEMS AND METHODS FOR EX-LIVE ORGAN CARE.
US8304181B2 (en) 2004-10-07 2012-11-06 Transmedics, Inc. Method for ex-vivo organ care and for using lactate as an indication of donor organ status
US9078428B2 (en) 2005-06-28 2015-07-14 Transmedics, Inc. Systems, methods, compositions and solutions for perfusing an organ
CA2632630C (en) 2005-12-13 2016-12-06 President And Fellows Of Harvard College Scaffolds for cell transplantation
KR100809046B1 (en) * 2006-03-10 2008-03-03 가톨릭대학교 산학협력단 Self assembled nanoparticle having pullulan and methods of using thereof
CA2674949A1 (en) 2007-01-12 2008-07-24 J. Marc Simard Targeting ncca-atp channel for organ protection following ischemic episode
BRPI0807918A2 (en) * 2007-02-17 2017-05-16 Harvard College compositions and method for preserving tissue
KR100834687B1 (en) * 2007-02-21 2008-06-02 주식회사 엘지생활건강 Lipid nano-particle containing hinokitiol and manufacturing method thereof
US9457179B2 (en) 2007-03-20 2016-10-04 Transmedics, Inc. Systems for monitoring and applying electrical currents in an organ perfusion system
KR100785656B1 (en) * 2007-05-14 2007-12-17 재단법인서울대학교산학협력재단 Sodium glycocholate or derivatives thereof used as anti-inflammatory agents
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
FR2919785B1 (en) * 2007-08-09 2017-10-20 Hemarina Sa USE OF AN EXTRACELLULAR GLOBIN, EXTRACELLULAR GLOBIN OR EXTRACELLOUS PROTOMER FOR THE PRESERVATION OF ORGANS, TISSUES, OR CELLS OF ORGANS OR TISSUES, OR THE CULTURE OF CELLS
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
EP2254602B1 (en) 2008-02-13 2018-11-21 President and Fellows of Harvard College Continuous cell programming devices
WO2010128159A1 (en) * 2009-05-07 2010-11-11 Hemarina Novel heamoglobin and uses thereof
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
US8728456B2 (en) 2009-07-31 2014-05-20 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
EP2530142B1 (en) 2010-01-29 2018-03-14 Organ Technologies Inc. Perfusion culture method and perfusion culture device for organ or tissue
EP2540306B1 (en) * 2010-02-23 2015-03-25 Terumo Kabushiki Kaisha Additive for erythrocyte-rich solution, and container for medical purposes
PL2624873T3 (en) 2010-10-06 2020-12-14 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
CN103502436A (en) * 2011-03-07 2014-01-08 麻省理工学院 Methods for transfecting cells with nucleic acids
AU2012242578B2 (en) 2011-04-14 2016-07-21 Transmedics, Inc. Organ care solution for ex-vivo machine perfusion of donor lungs
WO2012149358A1 (en) 2011-04-28 2012-11-01 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
GB201107466D0 (en) 2011-05-05 2011-06-15 Loktionov Alexandre Device and method for non-invasive collection of colorectal mucocellular layer and disease detection
CA2838125A1 (en) 2011-06-03 2012-12-06 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
AU2012335070A1 (en) * 2011-11-11 2014-05-29 Bio-Ess Laboratories, Llc Kit comprising serum replacement and labile factors
PT2838515T (en) 2012-04-16 2020-02-25 Harvard College Mesoporous silica compositions for modulating immune responses
CN103461322B (en) * 2012-06-07 2016-08-03 西比曼生物科技（上海）有限公司 The preservation liquid of the cell after cryopreservation resuscitation
KR101426804B1 (en) * 2012-10-09 2014-08-05 김홍승 Platelet preserving composition, and kit for preserving platelet, and method for preserving platelet using the same
PL2934109T3 (en) * 2012-11-30 2022-03-21 Pharmacosmos Holding A/S Cryoprotecting agent, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation
EP3071030B1 (en) * 2013-11-21 2020-03-25 Jayachandran Kizhakkedathu Polymer based transplant preservation solution
MX2016008251A (en) * 2013-12-20 2016-10-13 Essential Pharmaceuticals Llc Media for cell culture.
IL282010B (en) 2013-12-24 2022-07-01 Univ Virginia Commonwealth Uses of oxygenated cholesterol sulfates
CN103931607A (en) * 2014-04-04 2014-07-23 湖南苗王生物科技有限公司 Vitrification freezing method for sturgeon sperms
WO2015168379A2 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
ES2839202T3 (en) 2014-06-02 2021-07-05 Transmedics Inc Ex vivo organ care system
KR101668743B1 (en) * 2014-08-08 2016-10-25 (주)세포바이오 A composition for preserving cells comprising plant-derived recombinant human serum albumin and plant peptide
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
JP7094533B2 (en) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ Immune cell capture device and its manufacture and use
CN115287226A (en) 2015-06-30 2022-11-04 雀巢产品有限公司 Composition suitable for protecting microorganisms
US10791730B2 (en) * 2016-01-14 2020-10-06 DePuy Synthes Products, Inc. Composition and methods for cryopreservation of hUTC
JP7138864B2 (en) 2016-02-06 2022-09-20 プレジデント アンド フェローズ オブ ハーバード カレッジ Recapitulation of the hematopoietic niche to reconstitute immunity
CN107232186B (en) * 2016-03-06 2018-09-21 郑州欧范医疗器械有限公司 A kind of cells frozen storing liquid of human adipose-derived stem cell
EP3484448A4 (en) 2016-07-13 2020-04-01 President and Fellows of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
CN106613148A (en) * 2016-11-19 2017-05-10 蚌埠市涂山村富民石榴专业合作社 Greenhouse blanched garlic leaf planting method achieving multiple times of harvesting
CN106689115A (en) * 2016-11-30 2017-05-24 广州赛莱拉干细胞科技股份有限公司 Umbilical cord preservation solution and application thereof
CN106434532A (en) * 2016-12-22 2017-02-22 叶宗耀 Culture medium for culturing hepatocytes and preparation method thereof
CN106857501B (en) * 2017-02-22 2021-09-24 单纯 Storage liquid for storing rat liver homogenate S9 and preparation method thereof
CN107041362B (en) * 2017-05-23 2020-12-22 天晴干细胞股份有限公司 Deep low-temperature freezing method for tumor tissue blocks
CN107624753A (en) * 2017-09-19 2018-01-26 北京瑞格瑞特生物科技有限公司 A kind of hypoxic voltage stabilizing transportation resources
WO2019143969A1 (en) 2018-01-18 2019-07-25 Claudio Maldonado Treating microvascular dysfunction
CA3129732A1 (en) * 2019-02-14 2020-08-20 North Grove Investments, Inc. Compositions for maintaining the viability of living and static biological material, methods of making and the uses thereof
CN110012901B (en) * 2019-04-12 2021-06-01 西北农林科技大学 Diluting preparation for preserving boar semen at normal temperature
KR102344674B1 (en) * 2019-06-19 2021-12-29 가천대학교 산학협력단 Composition for preventing organ damage during preserving organ for transplantation containing 8-oxo-2'-deoxyguanosine as an active ingredient
JPWO2021090869A1 (en) * 2019-11-08 2021-05-14
US20230081507A1 (en) 2020-02-26 2023-03-16 Finless Foods Inc. Systems and methods for live fish tissue preservation
CN112514892B (en) * 2020-12-25 2022-06-14 广州赛莱拉干细胞科技股份有限公司 Exosome cryopreservation protection solution and preparation method thereof
WO2023023309A1 (en) 2021-08-20 2023-02-23 Finless Foods Inc. Systems and methods for fish tissue preservation
CN113973808A (en) * 2021-11-15 2022-01-28 深圳市人民医院 Improved cell cryopreservation liquid formula
CN114600872A (en) * 2022-04-13 2022-06-10 西安北光医学生物技术有限公司 Method and system for anti-damage preservation of cells, tissues or organs
CN114698630B (en) * 2022-06-06 2022-08-23 天津百恩生物科技有限公司 Placenta tissue preserving fluid and preparation method and application thereof
CN115349514B (en) * 2022-07-08 2024-02-27 杭州联川生物技术股份有限公司 Fresh tissue frozen stock solution and preparation method and application thereof

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0076647A2 (en) * 1981-10-02 1983-04-13 HANA Biologics Incorporated Culture media for cells originating from the immune system
US4533637A (en) * 1981-05-28 1985-08-06 Ajinomoto Co., Inc. Culture medium
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
US5104787A (en) * 1990-03-05 1992-04-14 Lindstrom Richard L Method for apparatus for a defined serumfree medical solution useful for corneal preservation
US5221668A (en) * 1992-02-26 1993-06-22 Abbott Laboratories Nutritional product for trauma and surgery patients
US5232848A (en) * 1987-03-24 1993-08-03 W. R. Grace & Co.-Conn. Basal nutrient medium for cell culture
US5405742A (en) * 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same
US5468635A (en) * 1990-04-17 1995-11-21 Nippon Oil Co., Ltd. In vitro method for stimulating cell growth by culturing cells in a serum-free culture medium comprising human lysozyme
US5474931A (en) * 1991-06-17 1995-12-12 Life Technologies, Inc. Media concentrate technology
US5599659A (en) * 1993-03-11 1997-02-04 Breonics, Inc. Preservation solution for ex vivo, warm preservation of tissues, explants,organs and vascular endothelial cells comprising retinal-derived fibroblast growth factor, cyclodextrin and chondroitin sulfate
US5658575A (en) * 1993-09-07 1997-08-19 L'oreal Cosmetic or dermatological composition comprising an oil-in-water emulsion based on oily globules provided with a lamellar liquid crystal coating
US5712163A (en) * 1989-06-05 1998-01-27 Organogenesis, Inc. Chemically defined cell culture media and system and methods for use, particularly for culturing epithelial cells
US6153582A (en) * 1998-11-05 2000-11-28 Bausch & Lomb Surgical, Inc. Defined serumfree medical solution for ophthalmology
US6303375B1 (en) * 1998-06-23 2001-10-16 Terumo Kabushiki Kaisha Cell supporting matrix, cell culture device, and fluid treating device
US20020012988A1 (en) * 1999-04-14 2002-01-31 Lauren Brasile Organ chamber for exsanguinous metabolic support system
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
US6406909B1 (en) * 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
US6416740B1 (en) * 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US20020090369A1 (en) * 2000-07-28 2002-07-11 Murphy Chistopher J. Transplant media
US20020119567A1 (en) * 2000-06-23 2002-08-29 Chiarello Ronald H. Cost effective media for large scale insect cell culture

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1A (en) * 1836-07-13 John Ruggles Locomotive steam-engine for rail and other roads
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4663166A (en) 1984-06-22 1987-05-05 Veech Richard L Electrolyte solutions and in vivo use thereof
US4879283A (en) 1985-10-03 1989-11-07 Wisconsin Alumni Research Foundation Solution for the preservation of organs
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
AU2255488A (en) * 1987-07-24 1989-03-01 Cetus Corporation Lipid microemulsions for culture media
US5061481A (en) 1989-03-20 1991-10-29 Kobayashi Kose Co., Ltd. Cosmetic composition having acryl-silicone graft copolymer
JPH03180176A (en) * 1989-11-16 1991-08-06 W R Grace & Co Nutrient medium for cell culture
US5066578A (en) 1989-12-21 1991-11-19 The Regents Of The University Of California Long-term preservation of organs for transplantation
JPH0459735A (en) * 1990-06-27 1992-02-26 Terumo Corp Hemoglobin-containing liposome
JP2956998B2 (en) * 1990-10-11 1999-10-04 テルモ株式会社 Preservative solution for transplant organ perfusion and preservation method for transplant organ perfusion
WO1993009220A1 (en) 1991-11-06 1993-05-13 Correa Paulo N Cell culture medium
US6291424B1 (en) 1991-11-14 2001-09-18 Brigham And Women's Hospital Nitrosated and nitrosylated heme proteins
DE69329073T2 (en) 1992-03-23 2001-01-18 Georgetown University Washingt TAXOL ENCLOSED IN LIPOSOMES AND METHOD OF USE
US5370989A (en) 1992-04-03 1994-12-06 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5637315A (en) * 1993-01-04 1997-06-10 Thomas Jefferson University Treatment of disease states induced by oxidative stress
WO1994022482A1 (en) 1993-03-26 1994-10-13 Biorelease Technologies, Inc. Compositions including heme-containing proteins and methods relating thereto
US5405772A (en) * 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
CA2169272A1 (en) 1993-08-12 1995-02-23 John J. Lemasters Rinse solutions for organs and tissues
US5428039A (en) 1994-02-20 1995-06-27 The Center For Innovative Technology Method for electively achieving reversible hyperpolarized cardiac arrest
US5543316A (en) * 1994-04-20 1996-08-06 Diacrin, Inc. Injectable culture medium for maintaining viability of myoblast cells
AU7071896A (en) 1995-09-14 1997-04-01 Lxr Biotechnology Inc. Compositions with anti-apoptotic activity, containing a mixture of phospholipids
US5670545A (en) 1996-02-09 1997-09-23 Board Of Regents Of The University Of Colorado Method for the treatment of ischemic disease and reperfusion injury and the prevention of the adverse effects of reactive oxygen species
US5897987A (en) * 1996-03-25 1999-04-27 Advanced Reproduction Technologies, Inc. Use of arabinogalactan in cell cryopreservation media
US5696152A (en) * 1996-05-07 1997-12-09 Wisconsin Alumni Research Foundation Taxol composition for use as organ preservation and cardioplegic agents
US5843024A (en) 1996-05-17 1998-12-01 Breonics, Inc. Solution and process for resuscitation and preparation of ischemically damaged tissue
EP0960130A4 (en) 1996-09-27 2001-01-31 Trustees For The Board Of Oxygen-binding heme proteins incorporating circularly-permuted globins
US6274305B1 (en) * 1996-12-19 2001-08-14 Tufts University Inhibiting proliferation of cancer cells
DE69836972D1 (en) * 1997-03-19 2007-03-15 Sky High Llc COMPOSITIONS CONTAINING LYSOPHOPHASIC ACID THAT PREVENT THE APOPTOSIS AND ITS USE
US6495532B1 (en) 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US5834178C1 (en) * 1997-07-09 2002-04-23 Univ Wayne State Flush-storage solution for donor organs
US5948609A (en) 1997-12-03 1999-09-07 Carter; Daniel C. Oxygen-transporting albumin-based blood replacement composition and blood volume expander
CA2324208C (en) * 1998-03-18 2009-06-30 Massachusetts Institute Of Technology Vascularized perfused microtissue/micro-organ arrays
ATE372377T1 (en) * 1998-03-30 2007-09-15 Mibelle Ag Cosmetics USE OF NANOEMULSIONS TO DETERMINE THE BIOCOMPATIBILITY OF LIPOPHILIC SUBSTANCES IN CELL CULTURE TEST AND SUITABLE NANOEMULSIONS
US6204375B1 (en) * 1998-07-31 2001-03-20 Ambion, Inc. Methods and reagents for preserving RNA in cell and tissue samples
US6200590B1 (en) * 1998-08-10 2001-03-13 Naphcare, Inc. Controlled, phased-release suppository and its method of production
FR2793495B1 (en) * 1999-05-14 2001-08-10 Imv Technologies THINNER FOR CRYOPRESERVATION OF CATTLE SPERMATOZOIDS
US7198895B2 (en) * 2000-11-14 2007-04-03 Mohanlal Ramon W In vitro cell-based methods for biological validation and pharmacological screening of chemical entities and biologicals
WO2003017987A1 (en) * 2001-08-31 2003-03-06 Mcgill University Biodegradable polymeric nanocapsules and uses thereof
EP1475434A1 (en) * 2003-05-09 2004-11-10 Oncoscience AG Method for storing tumor cells

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4533637A (en) * 1981-05-28 1985-08-06 Ajinomoto Co., Inc. Culture medium
EP0076647A2 (en) * 1981-10-02 1983-04-13 HANA Biologics Incorporated Culture media for cells originating from the immune system
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
US5232848A (en) * 1987-03-24 1993-08-03 W. R. Grace & Co.-Conn. Basal nutrient medium for cell culture
US5712163A (en) * 1989-06-05 1998-01-27 Organogenesis, Inc. Chemically defined cell culture media and system and methods for use, particularly for culturing epithelial cells
US5104787A (en) * 1990-03-05 1992-04-14 Lindstrom Richard L Method for apparatus for a defined serumfree medical solution useful for corneal preservation
US5468635A (en) * 1990-04-17 1995-11-21 Nippon Oil Co., Ltd. In vitro method for stimulating cell growth by culturing cells in a serum-free culture medium comprising human lysozyme
US5474931A (en) * 1991-06-17 1995-12-12 Life Technologies, Inc. Media concentrate technology
US5221668A (en) * 1992-02-26 1993-06-22 Abbott Laboratories Nutritional product for trauma and surgery patients
US5599659A (en) * 1993-03-11 1997-02-04 Breonics, Inc. Preservation solution for ex vivo, warm preservation of tissues, explants,organs and vascular endothelial cells comprising retinal-derived fibroblast growth factor, cyclodextrin and chondroitin sulfate
US5405742A (en) * 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same
US5658575A (en) * 1993-09-07 1997-08-19 L'oreal Cosmetic or dermatological composition comprising an oil-in-water emulsion based on oily globules provided with a lamellar liquid crystal coating
US6416740B1 (en) * 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6303375B1 (en) * 1998-06-23 2001-10-16 Terumo Kabushiki Kaisha Cell supporting matrix, cell culture device, and fluid treating device
US6406909B1 (en) * 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
US6153582A (en) * 1998-11-05 2000-11-28 Bausch & Lomb Surgical, Inc. Defined serumfree medical solution for ophthalmology
US20020012988A1 (en) * 1999-04-14 2002-01-31 Lauren Brasile Organ chamber for exsanguinous metabolic support system
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
US20020119567A1 (en) * 2000-06-23 2002-08-29 Chiarello Ronald H. Cost effective media for large scale insect cell culture
US20020090369A1 (en) * 2000-07-28 2002-07-11 Murphy Chistopher J. Transplant media

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1624750A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105284786A (en) * 2015-10-15 2016-02-03 广州赛莱拉干细胞科技股份有限公司 Cell preservation liquid and application thereof in protecting megakaryocyte progenitor cell activity

Also Published As

Publication number Publication date
WO2004101758A2 (en) 2004-11-25
CN1784142A (en) 2006-06-07
JP2007524368A (en) 2007-08-30
US7604933B2 (en) 2009-10-20
US7220538B2 (en) 2007-05-22
WO2004099393A1 (en) 2004-11-18
US7537885B2 (en) 2009-05-26
US20070042338A1 (en) 2007-02-22
JP4870551B2 (en) 2012-02-08
MXPA05012070A (en) 2006-06-23
AU2004239310A1 (en) 2004-11-25
AU2004236402A1 (en) 2004-11-18
AU2004239310B2 (en) 2010-06-17
ZA200509760B (en) 2006-11-29
CN1816617A (en) 2006-08-09
RU2005138320A (en) 2006-04-27
US20050037330A1 (en) 2005-02-17
EP1475434A1 (en) 2004-11-10
BRPI0410185A (en) 2006-05-16
CA2523417C (en) 2013-04-30
JP5192694B2 (en) 2013-05-08
EP1624750A4 (en) 2006-10-25
US20070178435A1 (en) 2007-08-02
CA2526933A1 (en) 2004-11-25
EP1624750A2 (en) 2006-02-15
EP1623021A1 (en) 2006-02-08
EP1624750B1 (en) 2015-12-30
JP2007502130A (en) 2007-02-08
CA2523417A1 (en) 2004-11-18
CA2526933C (en) 2013-02-12
CN1816617B (en) 2010-12-01
KR20060019525A (en) 2006-03-03
AU2004236402B2 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
WO2004101758A3 (en) Composition for maintaining organ and cell viability
WO2003000114A3 (en) Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
WO2006081435A3 (en) Method of providing readily available cellular material derived from cord blood, and a composition thereof
WO2004009767A3 (en) Cell therapy for regeneration
WO2009045360A3 (en) Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
EP2530157A3 (en) Oligomeric compounds and compositions for use in modulation of small non-coding rnas
IL164079A0 (en) Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
WO2005014839A3 (en) Monatin tabletop sweetener compositions and methods of making same
EP2450433A3 (en) Methods of preparing and using stem cell compositions and kits comprising the same
WO2007035843A3 (en) Methods and compositions for organ and tissue functionality
WO2006093857A3 (en) Method of providing readily available cellular material derived from peripheral blood and a composition thereof
WO2005000245A3 (en) Compositions and methods for increasing telomerase activity
AU2003273276A8 (en) Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
WO2005041656A3 (en) Methods, compositions and devices for inducing stasis in tissues and organs
EP1780267A3 (en) Amniotic fluid derived cells
ATE470443T1 (en) INDOL-1-YL ACID DERIVATIVES
WO2006124892A3 (en) Modulators of alpha-synuclein toxicity
WO2005000248A3 (en) Compositions and methods for skin conditioning
WO2007064846A3 (en) COMPOSITIONS AND METHODS OF USING siRNA TO KNOCKDOWN GENE EXPRESSION AND TO IMPROVE SOLID ORGAN AND CELL TRANSPLANTATION
WO2007025166A3 (en) Devices, compositions and methods for the protection and repair of cells and tissues
WO2006047841A3 (en) Engineering with homing factors
WO2003012060A3 (en) Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
WO2005021706A3 (en) Delivery of compounds with rehydrated blood cells
WO2006093860A3 (en) Method and composition for repairing heart tissue
WO2009047568A3 (en) In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004239310

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 171808

Country of ref document: IL

Ref document number: 2006532912

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057021228

Country of ref document: KR

Ref document number: 543449

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2526933

Country of ref document: CA

Ref document number: PA/a/2005/012070

Country of ref document: MX

Ref document number: 20048125711

Country of ref document: CN

Ref document number: 1251/MUMNP/2005

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004239310

Country of ref document: AU

Date of ref document: 20040507

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004239310

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004751778

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200509760

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005138320

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004751778

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057021228

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0410185

Country of ref document: BR